I1-MMAE

I1-MMAE is an experimental antibody-drug conjugate (ADC) targeting Intercellular Adhesion Molecule 1 (ICAM1), a cell surface glycoprotein frequently overexpressed in various cancers, including melanoma. The conjugate consists of a specific anti-ICAM1 monoclonal antibody (clone I1) linked to the potent cytotoxic payload Monomethyl Auristatin E (MMAE). MMAE is a synthetic antimitotic agent that inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. Upon binding to ICAM1 on the tumor cell surface, the ADC is internalized via endocytosis, and the MMAE payload is released within the lysosomal compartment. Preclinical research suggests that the efficacy of I1-MMAE can be significantly enhanced when combined with epigenetic modulators like decitabine, which upregulate ICAM1 expression and improve the penetration and internalization of the ADC within the tumor microenvironment.

Other names

ICAM1-MMAEICAM-1-MMAEICAM 1-MMAEanti-ICAM1-MMAEanti-ICAM-1-MMAEanti-ICAM 1-MMAEI1-vcMMAEI-1-vcMMAEI 1-vcMMAE